Structure via PubChem · Public domain (PubChem)
sunitinib
Sign in to saveSunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
Chemical data
- Formula
- C22H27FN4O2
- Molecular weight
- 398.5 g/mol
- IUPAC name
- N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
- SMILES
- CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C
- InChIKey
- WINHZLLDWRZWRT-ATVHPVEESA-N
- XLogP
- 2.6
- Polar surface area
- 77.2 Ų
- H-bond donors
- 3
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
8,400 papers- Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023
- Sunitinib-induced thrombotic microangiopathy.Journal of cancer research and therapeutics · 2016
- Sunitinib in the Treatment of Thyroid Cancer.Current medicinal chemistry · 2019
- Sunitinib.Drugs · 2006
- AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.International journal of biological sciences · 2023
via PubMed
~14 min read
Encyclopedic overview
21 sectionsContents
- Medical uses
- Gastrointestinal stromal tumor
- Meningioma
- Aggressive fibromatosis
- Pancreatic neuroendocrine tumors
- Renal cell carcinoma
- Mechanism of action
- History
- Side effects
- Interactions
- Society and culture
- Economics
- US
- UK
- AU
- Research
- Other solid tumors
- Leukemia
- Unsuccessful trials
- References
- External links
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
As of August 2021, sunitinib is available as a generic medicine in the US.
Excerpted from Wikipedia’s “sunitinib” article, available under the CC BY-SA 4.0 licence.